[Gastrointestinal stromal tumor].
Gastrointestinal stromal tumors (GISTs), the most common submucosal tumor in the gut, express the KIT protein. Gain-of-function mutations in the KIT or PDGF-R alpha gene is involved in oncogenesis and growth of GISTs. Although the first-line therapy of resectable GISTs is surgery, imatinib mesylate, a target-based molecule against KIT and PDGF-R alpha proteins, showed remarkable clinical effects and good tolerability for non-resectable GISTs. Now, imatinib is in the first-line for non-resectable GISTs. Resistance against imatinib, however, is proved after long-standing use of the drug.
Nishida
Toshirou
T
Dept. of Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita 565-0871, Japan.
Ohmori
Takeshi
T
Matsuda
Hikaru
H
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D005770:Gastrointestinal Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D006801:Humans; D000068877:Imatinib Mesylate; D009154:Mutation; D010879:Piperazines / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D019009:Proto-Oncogene Proteins c-kit / Q000096:biosynthesis* / Q000235:genetics*; D011743:Pyrimidines / Q000627:therapeutic use; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D019009:Proto-Oncogene Proteins c-kit; D020796:Receptor, Platelet-Derived Growth Factor alpha